Clinical protocol
ENZARAD (ANZUP 1303): a randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer
ANZUP
DoseLab summary
Phase 3 ANZUP trial protocol. Citation as given in the eviQ reference list; eviQ gives no further publication details, so the link is a search.
Why this is useful
Trial protocol whose rectal, bladder and femoral head limits eviQ uses for conventionally fractionated prostate and prostate bed treatment.
Reference details
- Title
- ENZARAD (ANZUP 1303): a randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer
- Authors / organization
- ANZUP
- Publication / protocol
- ENZARAD / ANZUP 1303 trial protocol
- Version
- Pending verification
- Year
- 2015
- DOI
- Pending verification
- Disease sites
- Prostate
- Topics
- Prostate, Dose Constraints, Protocols
- Fractionation context
- Conventional
- Last reviewed by DoseLab
- Pending verification